GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
Eli Lilly and Co enters a critical period of expanding diet drug production, welcoming a new CFO.
US pharmaceutical giant Eli Lilly and Co. announced that Lucas Montarce, a senior financial expert within the company, has been appointed as the Chief Financial Officer, and the appointment is effective immediately. This personnel change comes at a critical moment as Eli Lilly is investing billions of dollars to expand production to meet the increasing demand for its diabetes and weight loss drugs (such as Mounjaro and Zepbound). Despite FDA approval, Eli Lilly still faces supply shortages.
A Glimpse Into The Expert Outlook On Eli Lilly Through 28 Analysts
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Why Is Moderna Stock Trading Higher On Monday?
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
Pfizer Analyst Ratings
MonkeyGee OP : This the pump this morning get you?
MonkeyGee OP : This is not looking good. and given what happened this morning with bigboys doing a fake pump to unload. They have taken the position on where they want to drive this stock. When (not if) this start to dip, it will be extremely violent since the rubberband is stretched to high tension. Snapback will HURT.